全文获取类型
收费全文 | 215076篇 |
免费 | 17731篇 |
国内免费 | 6863篇 |
专业分类
耳鼻咽喉 | 1250篇 |
儿科学 | 7630篇 |
妇产科学 | 1542篇 |
基础医学 | 18969篇 |
口腔科学 | 3599篇 |
临床医学 | 22861篇 |
内科学 | 54495篇 |
皮肤病学 | 2721篇 |
神经病学 | 25707篇 |
特种医学 | 6223篇 |
外国民族医学 | 4篇 |
外科学 | 16468篇 |
综合类 | 29885篇 |
现状与发展 | 32篇 |
一般理论 | 9篇 |
预防医学 | 17074篇 |
眼科学 | 2332篇 |
药学 | 15025篇 |
184篇 | |
中国医学 | 9916篇 |
肿瘤学 | 3744篇 |
出版年
2024年 | 223篇 |
2023年 | 4345篇 |
2022年 | 5834篇 |
2021年 | 10869篇 |
2020年 | 10965篇 |
2019年 | 8332篇 |
2018年 | 8250篇 |
2017年 | 8196篇 |
2016年 | 8516篇 |
2015年 | 8224篇 |
2014年 | 15582篇 |
2013年 | 17067篇 |
2012年 | 12757篇 |
2011年 | 13792篇 |
2010年 | 10850篇 |
2009年 | 10441篇 |
2008年 | 10448篇 |
2007年 | 10104篇 |
2006年 | 9006篇 |
2005年 | 7426篇 |
2004年 | 6319篇 |
2003年 | 5425篇 |
2002年 | 4573篇 |
2001年 | 3950篇 |
2000年 | 3270篇 |
1999年 | 2719篇 |
1998年 | 2442篇 |
1997年 | 2093篇 |
1996年 | 1862篇 |
1995年 | 1926篇 |
1994年 | 1778篇 |
1993年 | 1513篇 |
1992年 | 1453篇 |
1991年 | 1280篇 |
1990年 | 1011篇 |
1989年 | 859篇 |
1988年 | 807篇 |
1987年 | 734篇 |
1986年 | 633篇 |
1985年 | 737篇 |
1984年 | 617篇 |
1983年 | 379篇 |
1982年 | 446篇 |
1981年 | 377篇 |
1980年 | 283篇 |
1979年 | 247篇 |
1978年 | 185篇 |
1977年 | 164篇 |
1976年 | 136篇 |
1975年 | 49篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
81.
目前已用出生免疫错误(IEI)来替代原发性免疫缺陷病这一概念。IEI是一类由单基因突变引起免疫功能异常的遗传性疾病,肝脏和脾脏作为人类重要的免疫器官,与IEI疾病过程中伴发感染、淋巴增殖及自身免疫现象等有重要关联。文章就与IEI相关的肝脾问题进行概述。 相似文献
82.
宫腔化脓性感染是一种严重的盆腔炎性疾病(PID),主要表现为发热、腹痛、阴道分泌物增多等症状。椎间盘炎是发生于椎间盘间隙和邻近椎体或软骨板的感染性病变,其症状及体征缺乏特异性,临床上容易诊断延迟直至出现椎体骨质破坏及下肢肌力减弱。本文报道了1例因取环手术引发宫腔化脓性感染进而引发腰椎间盘炎,出现腰痛伴行走障碍的患者,并进行了文献复习,加深了对PID的病原体、感染传播途径、诊断标准、治疗原则及其严重不良后果的认识。对于非特异性椎间隙感染,临床医生除实验室检查及影像学检查之外,还应仔细询问病史并了解病情的演变过程,及时诊断并进行手术治疗。 相似文献
83.
《Saudi Pharmaceutical Journal》2022,30(11):1572-1588
Non-alcoholic fatty liver disease (NAFLD) is one of the most common complications of a metabolic syndrome caused by excessive accumulation of fat in the liver. Orthosiphon stamineus also known as Orthosiphon aristatus is a medicinal plant with possible potential beneficial effects on various metabolic disorders. This study aims to investigate the in vitro inhibitory effects of O. stamineus on hepatic fat accumulation and to further use the computational systems pharmacology approach to identify the pharmacokinetic properties of the bioactive compounds of O. stamineus and to predict their molecular mechanisms against NAFLD. Methods: The effects of an ethanolic extract of O. stamineus leaves on cytotoxicity, fat accumulation and antioxidant activity were assessed using HepG2 cells. The bioactive compounds of O. stamineus were identified using LC/MS and two bioinformatics databases, namely the Traditional Chinese Medicine Integrated Database (TCMID) and the Bioinformatics Analysis Tool for the Molecular Mechanism of Traditional Chinese Medicine (BATMAN-TCM). Pathway enrichment analysis was performed on the predicted targets of the bioactive compounds to provide a systematic overview of the molecular mechanism of action, while molecular docking was used to validate the predicted targets. Results: A total of 27 bioactive compounds corresponding to 50 potential NAFLD-related targets were identified. O. stamineus exerts its anti-NAFLD effects by modulating a variety of cellular processes, including oxidative stress, mitochondrial β-oxidation, inflammatory signalling pathways, insulin signalling, and fatty acid homeostasis pathways. O. stamineus is significantly targeting many oxidative stress regulators, including JNK, mammalian target of rapamycin (mTOR), NFKB1, PPAR, and AKT1. Molecular docking analysis confirmed the expected high affinity for the potential targets, while the in vitro assay indicates the ability of O. stamineus to inhibit hepatic fat accumulation. Conclusion: Using the computational systems pharmacology approach, the potentially beneficial effect of O. stamineus in NAFLD was indicated through the combination of multiple compounds, multiple targets, and multicellular components. 相似文献
84.
Conan MacDougall Theora Canonica Chris Keh Binh An P. Phan Janice Louie 《Pharmacotherapy》2022,42(4):343-361
Rifamycins (rifampin, rifabutin, and rifapentine) play an essential role in the treatment of mycobacterial and some nonmycobacterial infections. They also induce the activity of various drug transporting and metabolizing enzymes, which can impact the concentrations and efficacy of substrates. Many anticoagulant and antiplatelet (AC/AP) agents are substrates of these enzymes and have narrow therapeutic indices, leading to risks of thrombosis or bleeding when coadministered with rifamycins. The objective of this systematic review was to evaluate the effects on AC/AP pharmacokinetics, laboratory markers, and clinical safety and efficacy of combined use with rifamycins. A systematic review following the Preferred Reporting Items for Systematic Reviews and Meta-analyses guidance was performed. The PubMed, Embase, and Web of Science databases were queried for English-language reports on combination use of rifamycins and AC/AP agents from database inception through August 2021. The 29 studies identified examined warfarin (n = 17), direct oral anticoagulants (DOACs) (n = 8), and antiplatelet agents (n = 4) combined with rifampin (n = 28) or rifabutin (n = 1). Eleven studies were case reports or small case series; 14 reported on pharmacokinetic or laboratory markers in healthy volunteers. Rifampin-warfarin combinations led to reductions in warfarin area under the curve (AUC) of 15%–74%, with variability by warfarin isomer and study. Warfarin dose increases of up to 3–5 times prerifampin doses were required to maintain coagulation parameters in the therapeutic range. DOAC AUCs were decreased by 20%–67%, with variability by individual agent and with rifampin versus rifabutin. The active metabolite of clopidogrel increased substantially with rifampin coadministration, whereas prasugrel was largely unaffected and ticagrelor saw decreases. Our review suggests most combinations of AC/AP agents and rifampin are problematic. Further studies are required to determine whether rifabutin or rifapentine could be safe alternatives for coadministration with AC/AP drugs. 相似文献
85.
86.
87.
《Revista portuguesa de cardiologia》2022,41(6):445-452
Introduction and ObjectivesThe 2019 ESC guidelines on chronic coronary syndromes updated the method for estimating the pre-test probability (PTP) of obstructive coronary artery disease (CAD). We aimed to compare the performance of the new PTP method against the 2013 prediction model in patients with stable chest pain undergoing coronary computed tomography angiography (CCTA) for suspected CAD.MethodsWe conducted a single-center cross-sectional study enrolling 320 consecutive patients undergoing CCTA for suspected CAD. Obstructive CAD was defined as any ≥50% luminal stenosis on CCTA. Whenever invasive coronary angiography was subsequently performed, patients were reclassified accordingly. The two PTP prediction models were assessed for calibration, discrimination and the ability to change the downstream diagnostic pathway.ResultsThe observed prevalence of obstructive CAD was 16.3% (n=52). The 2013 prediction model significantly overestimated the likelihood of obstructive CAD (relative overestimation of 130%, p=0.005), while the updated 2019 method showed good calibration (relative underestimation of 6.5%, p=0.712). The two approaches showed similar discriminative power, with C-statistics of 0.73 (95% CI: 0.66-0.80) and 0.74 (95% CI: 0.66-0.81) for the 2013 and 2019 methods, respectively (p=0.933). Reclassification of PTP using the new method resulted in a net reclassification improvement of 0.10 (p=0.001).ConclusionsThe updated 2019 prediction model provides a more accurate estimation of pre-test probabilities of obstructive CAD than the previous model. Adoption of this new score may improve disease prediction and influence the selection of non-invasive testing. 相似文献
88.
89.
《Saudi Pharmaceutical Journal》2022,30(2):108-111
Linezolid is an oxazolidinone antibiotic. Linezolid-associated lactic acidosis has been reported in 6.8% of linezolid-treated patients. Lactic acidosis is associated with poor clinical outcomes, with high blood lactate levels resulting in organ dysfunction and mortality. This case report describes the development of lactic acidosis in a 64-year-old Chinese woman who had received 33 days of treatment with antituberculosis drugs and 28 days of treatment with oral linezolid for tuberculous meningitis. Severe lactic acidosis was reversed by withdrawing antituberculosis drugs and using continuous venovenous hemodiafiltration (CVVH). When the patient's condition was stable, she was transferred to the infectious disease department, and antituberculosis drugs, with the exception of linezolid, were reintroduced. This did not result in recurrence of lactic acidosis. The causal relationship between lactic acidosis and linezolid was categorized as ‘probable’ on the Adverse Drug Reaction Probability Scale. This case demonstrates that CVVH has potential as an alternative to discontinuation of linezolid alone for rapid reversal of linezolid-associated severe lactic acidosis. 相似文献
90.